Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PNP | P00491 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32670321 | 1.00 | LMNA (0.44) | LMNAALDH1A1THRBKDM4ETSHR | |
| SCHEMBL4248406 | 1.00 | LMNA (0.44) | LMNAALDH1A1THRBKDM4ETSHR | |
| SCHEMBL2364466 | 0.97 | LMNA (0.47) | LMNAALDH1A1THRBKDM4EPNP | |
| SCHEMBL32670448 | 0.92 | KDM4E (0.44) | LMNAALDH1A1THRBKDM4ETSHR | |
| SCHEMBL14441406 | 0.88 | ALDH1A1 (0.37) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL18562075 | 0.88 | MAPT (0.36) | LMNAALDH1A1KDM4EMAPT | |
| SCHEMBL32670353 | 0.88 | THRB (0.40) | LMNAALDH1A1THRBKDM4E | |
| SCHEMBL6730640 | 0.87 | LMNA (0.38) | LMNAALDH1A1THRBKDM4E | |
| SCHEMBL4844804 | 0.86 | LMNA (0.42) | LMNAALDH1A1THRBKDM4E | |
| SCHEMBL3279037 | 0.86 | KDM4E (0.47) | LMNAALDH1A1THRBKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260038861-A1 | ANOLYTES COMPRISING ALKANOLAMINE-BASED LIGANDS FOR REDOX FLOW BATTERY SYSTEMS | BATTELLE MEMORIAL INSTITUTE (US) | 2026-02-05 | — | — | US | disclosed |
| US-20140235776-A1 | AMINOALCOHOL COMPOUNDS AND THEIR USE AS ZERO OR LOW VOC ADDITIVES FOR PAINTS AND COATINGS | ANGUS CHEMICAL COMPANY (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235776-A1 | AMINOALCOHOL COMPOUNDS AND THEIR USE AS ZERO OR LOW VOC ADDITIVES FOR PAINTS AND COATINGS | ANGUS CHEMICAL COMPANY (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2013016269-A1 | AMINOALCOHOL COMPOUNDS AND THEIR USE AS ZERO OR LOW VOC ADDITIVES FOR PAINTS AND COATINGS | ANGUS CHEMICAL COMPANY (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013016269-A1 | AMINOALCOHOL COMPOUNDS AND THEIR USE AS ZERO OR LOW VOC ADDITIVES FOR PAINTS AND COATINGS | ANGUS CHEMICAL COMPANY (US) | 2013-01-31 | — | — | WO | disclosed |
| EP-2011501-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use | Chelator LLC (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1261349-B1 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE | CHELATOR LLC (US) | 2008-09-03 | — | — | EP | disclosed |
| US-6881732-B2 | Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements | CHELATOR LLC (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1382332-A1 | Method for inhibiting bacterial or fungal growth using a polyamine derivative as complexing agent | Chelator LLC (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20040006055-A1 | Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements | CONCAT, LTD. A CALIFORNIA LIMITED PARTNERSHIP (US) | 2004-01-08 | — | — | US | disclosed |
| US-6583182-B1 | Atomic numbers 21-30 are components of enzymes required for nucleic acid replication; substituted polyaza compounds inhibit cell replication by decreaseing bioavailability of iron or copper | CHELATOR LLC | 2003-06-24 | — | — | US | disclosed |
| US-6387891-B2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN COSMETICS AND PERSONAL CARE PRODUCTS, INHIBITION OF METALLOENZYMES, AND INHIBITION OF REPERFUSION INJURY | CONCAT, LTD. | 2002-05-14 | — | — | US | disclosed |
| US-20010041170-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury | CHELATOR LLC | 2001-11-15 | — | — | US | disclosed |
| US-6264966-B1 | DEODORANTS; THERAPY FOR ORAL DISEASES | CONCAT, LTD. | 2001-07-24 | — | — | US | disclosed |
| US-6165996-A | Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis | CONCAT, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0955044-A2 | Method of inhibiting bacterial or fungal growth using a complexing agent | CONCAT LTD. (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5874573-A | Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy | CONCAT, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0841951-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS, AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT LTD. (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997001360-A9 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | — | 1997-07-17 | — | — | WO | disclosed |
| WO-1997001360-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT, LTD. (US) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260038861-A1 | ANOLYTES COMPRISING ALKANOLAMINE-BASED LIGANDS FOR REDOX FLOW BATTERY SYSTEMS | HAO2, ANO2, HRH4 | LMNA 4163/4885ALDH1A1 756/4885THRB 1579/4885 |
| US-20010041170-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury | MPO, LPO, SOD1 | LMNA 3170/4885ALDH1A1 267/4885THRB 2286/4885 |
| US-20040006055-A1 | Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements | SOD1, SLC39A11, SLC40A1 | LMNA 2599/4885ALDH1A1 361/4885THRB 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.